SparX Biopharma to present phase 1 clinical updates of SPX-303, a dual checkpoint bispecific antibody, during AACR 2025: Chicago Monday, April 21, 2025, 16:00 Hrs [IST] SparX Biop ...

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Crown BioScience experts explore organoid models and high-content imaging to evaluate T-cell-targeted therapies and ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Scientists could reshape cancer treatment by helping powerful drugs work better in the body by exploiting a surface protein called CD36 that helps pull substances into cells. This dramatically ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

Thanks to the tireless efforts of people like San Luis Obispo resident Frank Kalman and his nonprofit, End Kids Cancer, there have been major advances in pediatric oncology in recent years. Here's Kal ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...